| Document |
Document Title |
|
WO/2019/101729A1 |
The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of ra...
|
|
WO/2019/101789A1 |
The present invention relates to a combination of radioimmunoconjugates and a protein or molecule capable of leading to progression of the cell cycle through the G2/M checkpoint, a protein or molecule capable of inhibiting progression th...
|
|
WO/2019/099813A1 |
Systems and methods for using surgical meshes to deliver chemotherapeutic agents and radioactive elements are presented herein. The surgical mesh may comprise multiple layers, with an inner or outer layer comprising the radioactive eleme...
|
|
WO/2019/097101A1 |
The present invention describes a new method for functionalising proteins by incorporating a metal fragment of high-performance rhenium, thus producing coordinated iminopyridines having three carbonyl groups in the fac position which pro...
|
|
WO/2019/098291A1 |
This method uses a positron-emitting nuclide-labeled amino acid or a derivative thereof to synthesize a positron-emitting nuclide-labeled protein by means of a cell-free protein synthesis system. Said cell-free protein synthesis system i...
|
|
WO/2019/100005A1 |
The present invention generally relates to methods of theranostic compounds and their use to selectively kill a class of cancer cells. Methods and means related to the treatment of cancers which overexpress the KRAS gene and/or eIF5A gen...
|
|
WO/2019/094931A1 |
Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 ar...
|
|
WO/2019/091534A1 |
There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA- E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.
|
|
WO/2019/094657A1 |
The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, o...
|
|
WO/2019/092242A1 |
The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: A compound or a pharmaceutically acceptable salt thereof of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is ...
|
|
WO/2019/089575A1 |
The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and canc...
|
|
WO/2019/087957A1 |
This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered...
|
|
WO/2019/087425A1 |
Provided is a DNA comprising any of (a) to (c): (a) a DNA which comprises any of base sequences of from the 16th to 831st positions of SEQ ID NO: 1, from the 16th to 822nd positions of SEQ ID NO: 3, from the 16th to 825th positions of SE...
|
|
WO/2019/084696A1 |
Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.
|
|
WO/2019/084240A1 |
Methods for the treatment of a proliferative disorder include administration of a radiolabeled anti- CD45 antibody in concert with an adoptive cell therapy. The adoptive cell therapy may include administration of cells expressing a chime...
|
|
WO/2019/080941A1 |
This invention relates to certain novel tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors, their synthesis and their use for treating diseases. More particularly, this invention is directed to fused heterocyclic deri...
|
|
WO/2019/080504A1 |
Provided are a cell penetrating peptide and a cell penetrating peptide complex, as well as an application thereof. The cell penetrating peptide provided by the present invention is selected from the following amino acid sequences: an ami...
|
|
WO/2019/077032A1 |
The invention relates to a process of isolating samarium from a hydrophilic composition comprising nitrate ions, europium and samarium, by reducing europium(III) to europium(II) in this hydrophilic composition, and by extracting the sama...
|
|
WO/2019/075574A1 |
The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of β-glucocerebrosidase activity.
|
|
WO/2019/075583A1 |
This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is -(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded gly...
|
|
WO/2018/208137A9 |
The present invention relates to bilirubin derivative particles comprising a bilirubin derivative and a metal, a use thereof, and a manufacturing method therefor. Since the bilirubin derivative particles of the present invention form coo...
|
|
WO/2019/075413A1 |
Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for immun...
|
|
WO/2019/072238A1 |
A method for separating metal fullerene M@C82. The method comprises steps of: a) adding a Lewis acid to an extract containing metal fullerene M@C82 and reacting the same to generate a complex precipitate; b) washing the precipitate, foll...
|
|
WO/2019/068756A1 |
A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is acco...
|
|
WO/2019/068758A1 |
A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein the numbering is ...
|
|
WO/2019/068842A1 |
The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD14...
|
|
WO/2019/063634A1 |
The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which ...
|
|
WO/2019/065774A1 |
The present invention relates to a compound or the like which can be labeled with a wide variety of atoms, including atoms having a relatively large atomic radius, and which can give a radioactive drug with which accumulation in the kidn...
|
|
WO/2019/057598A1 |
The present invention is directed to a method for the preparation of a radiolabled conjugate composition comprising Bismuth-213 loaded targeting moieties that have been diluted with cold targeting moieties in a predetermined ratio of amo...
|
|
WO/2019/057445A1 |
It is therefore the objective of the present invention to provide minigastrin derivates which further improve the accumulation in CCK-2 receptor positive tumours by simultaneously very low accumulation in other organs, e.g. the kidneys. ...
|
|
WO/2019/056097A1 |
Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of su...
|
|
WO/2019/056098A1 |
Described herein are bioreductively- activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.
|
|
WO/2019/060770A1 |
The present disclosure provides compounds comprising a tetrapyrrole (e.g., a tetrapyrrole group) linked via a linker to one or more ligands and uses of the compounds. The compounds may be used as imaging agents (e.g., MRI contrast agents...
|
|
WO/2019/055706A1 |
Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin an...
|
|
WO/2019/052508A1 |
Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti...
|
|
WO/2019/054539A1 |
The present invention relates to a method for preparing Tc-99m by using nuclear resonance fluorescence, and a method for preparing Tc-99m generated through nuclear transformation by emitting photons at a Tc-99 nucleus existing at ground ...
|
|
WO/2019/051141A1 |
The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release n...
|
|
WO/2019/043026A1 |
Mesothelin (MSLN) has been found to be overexpressed in several human malignancies: 100% of epithelial mesotheliomas, the majority of pancreatic and ovarian adenocarcinomas, more than 50 % of lung adenocarcinomas and 34 to 67 % of triple...
|
|
WO/2019/044894A1 |
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...
|
|
WO/2019/040537A1 |
Disclosed are anti-HAAH antibodies and derivatives thereof conjugated to cytotoxic, cytostatic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions comprising the antibody- and antibody derivative-drug ...
|
|
WO/2019/035241A1 |
The present invention addresses the problem of providing an ameliorating agent for leukemia that uses an antibody. The problem is solved by an ameliorating agent for leukemia containing an anti-endoglin antibody.
|
|
WO/2019/032219A1 |
Lu-containing compositions comprising a particle coated by a Lu-containing film are disclosed. The process of depositing the Lu-containing film on the particle is also disclosed.
|
|
WO/2019/023787A1 |
The present invention is directed to a system, apparatus, and method for producing gallium radioisotopes on particle accelerators using solid targets and a Ga-68 composition produced by this method. The solid target assembly apparatus ha...
|
|
WO/2019/027033A1 |
Provided is an imaging agent of liver cancer or cancer that has occurred near the liver, the imaging agent containing radioactive trans-1-amino-3-fluorocyclobutane-1-carboxylic acid (fluciclovine) or a pharmacologically acceptable salt t...
|
|
WO/2019/027973A1 |
Pharmaceutical compositions comprising a radionuclide labelled monoclonal antibody against CD38, and methods of treating a hematological malignancy, inhibiting growth and/or proliferation of a cell expressing CD38, or treating a disease ...
|
|
WO/2019/023811A1 |
A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins s...
|
|
WO/2019/023148A1 |
Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.
|
|
WO/2019/020831A1 |
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties:(a)one or more ligands which are capable of binding to a disease-relevant target molecule, (b)a silicon-fl...
|
|
WO/2019/022611A2 |
The present invention relates to a vaccine composition for use in in vivo administration, comprising a (attenuated) pathogen or commensal modified to be a pre-targeting vector, the pre-targeting vector comprising one or more pendent reac...
|
|
WO/2019/022610A1 |
The present invention provides, in general, compositions comprising a microparticle-based pre-targeting vector comprising a diagnostic and/or therapeutic functionality, and a second component that selectively binds to the pre-targeting v...
|
